Pharnext kondigt herklassering aandelen vaste investeerder aan die positie van belangrijke aandeelhouders versterkt
PARIJS–(BUSINESS WIRE)– Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een Frans biofarmaceutisch bedrijf dat een geavanceerd portfolio van medicijnen tegen neurodegeneratieve ziekten ontwikkelt, is op de hoogte gesteld van een herklassering van de aandelen die in handen zijn van een grote investeerder.
De 2.143.736 aandelen in het bezit van Truffle Capital, medeoprichter van Pharnext met een belang van 19,9 procent in het bedrijf, zijn ondergebracht bij bestaande aandeelhouders, inclusief de twee belangrijke aandeelhouders Pierre Bastid (+ 600.000 aandelen) en Claude Berda (+1.243.736 aandelen). Truffle Capital laat weten dat de gemeenschappelijke beleggingsfondsen die de aandelen verkopen gedwongen waren uit deze investering te stappen, omdat ze het einde van hun looptijd hebben bereikt. Truffle Capital meldt tevens dat andere, nieuwe fondsen hebben geïnvesteerd in de beursgang van Pharnext in juli 2016.
Pharnext Announces Reclassification of Its Historical Investor’s Shares, Strengthening the Position of Core Shareholders |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PARIS–(BUSINESS WIRE)– Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, was informed of a reclassification of its historical investor’s shares. 2,143,736 shares held by Truffle Capital, co-founder of Pharnext, and representing 19.9% ownership of the company, have just been reclassified to existing shareholders including two core shareholders: Pierre Bastid (+600,000 shares) and Claude Berda (+1,243,736 shares). Truffle Capital states that the funds selling the shares are mutual investment funds that have reached maturity and therefore had a regulatory obligation to exit from their investments and, that other recent funds invested in Pharnext’s Initial Public Offering in July 2016. The initial lock-up commitments relating to the shares have been assumed in full by their new owners. After such reclassification, new ownership of Pharnext’s shares and voting rights are as follows:
About Pharnext Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several compositions of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, please visit www.pharnext.com View source version on businesswire.com: http://www.businesswire.com/news/home/20170329005943/en/ Contacts Pharnext |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||